Expand ABBV Menu
ABBV MENU

ABBV Latest Press Releases

-- September 11, 2024 --

Allergan Aesthetics Launches BOTOX Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China PRNewswire 8:30 AM

-- September 9, 2024 --

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs PRNewswire 9:00 AM

-- September 6, 2024 --

AbbVie Declares Quarterly Dividend PRNewswire 10:13 AM

-- September 5, 2024 --

NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines Business Wire 9:00 AM

-- September 4, 2024 --

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth Globe Newswire 9:15 AM
iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs Globe Newswire 7:00 AM

-- August 27, 2024 --

AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases PRNewswire 8:15 AM
SkinMedica Revolutionizes Skin Hydration with the Introduction of HA5 Hydra Collagen Replenish + Restore Hydrator PRNewswire 8:05 AM

-- August 19, 2024 --

European Commission Grants Second Indication Approval for TEPKINLY (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma PRNewswire 2:05 PM

-- August 1, 2024 --

AbbVie Completes Acquisition of Cerevel Therapeutics PRNewswire 8:23 AM

-- July 30, 2024 --

Allergan Aesthetics Celebrates the Second Annual JUVDERM Day PRNewswire 8:00 AM

-- July 28, 2024 --

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference 2024 (AAIC) Globe Newswire 8:05 AM

-- July 26, 2024 --

AbbVie Announces European Commission Approval of SKYRIZI (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PRNewswire 2:00 AM

-- July 25, 2024 --

Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected Globe Newswire 8:30 AM
AbbVie Reports Second-Quarter 2024 Financial Results PRNewswire 7:36 AM

-- July 12, 2024 --

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ) in Giant Cell Arteritis PRNewswire 8:30 AM

-- July 10, 2024 --

AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer PRNewswire 8:00 AM

-- July 2, 2024 --

AbbVie to Host Second-Quarter 2024 Earnings Conference Call PRNewswire 8:00 AM

-- July 1, 2024 --

Robert A. Michael Assumes Role as AbbVie Chief Executive Officer PRNewswire 8:00 AM

-- June 28, 2024 --

AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma PRNewswire 2:00 AM

-- June 27, 2024 --

AbbVie Acquires Celsius Therapeutics PRNewswire 9:26 AM
Introducing Alle Payment Plans, Powered by Cherry PRNewswire 8:30 AM

-- June 26, 2024 --

U.S. Food and Drug Administration Grants Second Approval for EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma PRNewswire 7:03 PM

-- June 25, 2024 --

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) PRNewswire 8:15 AM

-- June 21, 2024 --

AbbVie Declares Quarterly Dividend PRNewswire 8:00 AM

-- June 20, 2024 --

AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors PRNewswire 8:00 AM

-- June 18, 2024 --

U.S. FDA Approves SKYRIZI (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease PRNewswire 6:18 PM

-- June 14, 2024 --

AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer PRNewswire 4:08 PM

-- June 13, 2024 --

AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease PRNewswire 7:59 AM

-- June 11, 2024 --

BOTOX Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients PRNewswire 8:00 AM

-- June 6, 2024 --

AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer PRNewswire 8:45 AM
SkinMedica Celebrates 25 Years of Empowering Radiant Skin PRNewswire 8:30 AM
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers PRNewswire 8:00 AM

-- June 5, 2024 --

Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Business Wire 10:00 AM
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383 PRNewswire 9:00 AM

-- June 4, 2024 --

RINVOQ (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis PRNewswire 8:30 AM
Refer Your Friends to Alle, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50 PRNewswire 8:05 AM

-- June 3, 2024 --

AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference PRNewswire 8:30 AM

-- May 31, 2024 --

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PRNewswire 2:00 AM

-- May 29, 2024 --

Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Business Wire 1:04 PM

-- May 28, 2024 --

AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform PRNewswire 8:00 AM

-- May 24, 2024 --

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 Globe Newswire 8:45 AM

-- May 23, 2024 --

AbbVie Completes Acquisition of Landos Biopharma PRNewswire 4:05 PM

-- May 17, 2024 --

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week PRNewswire 7:30 AM

-- May 13, 2024 --

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders PRNewswire 8:39 AM

-- May 11, 2024 --

LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP Business Wire 1:29 PM

-- May 6, 2024 --

AbbVie to Present at the Bank of America Securities Healthcare Conference PRNewswire 8:00 AM

-- April 26, 2024 --

AbbVie Reports First-Quarter 2024 Financial Results PRNewswire 7:35 AM

-- April 25, 2024 --

New Data Show RINVOQ (upadacitinib) Demonstrated Superiority Versus DUPIXENT (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study PRNewswire 8:00 AM

-- April 23, 2024 --

Allergan Aesthetics Invites Consumers to Be the Face of BOTOX Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands PRNewswire 8:00 AM